Shots:

• The company has initiated the treatment of the first patients in the P-III clinical trial evaluating the safety & efficacy of BNT323/DB-1303 vs SoC single-agent CT in CT-naïve patients with HR+ & HER2-low metastatic breast cancer. The 1EP of the study includes PFS & 2EPs include OS, ORR, DoR & safety
• The P-III clinical trial is expected to enroll 532 patients at more than 223 clinical sites across the world incl. the US, China & Europe. Moreover, the P-III trial is based on the safety & efficacy data from the P-I/II clinical trial that depicted an ORR of 38.5% & a DCR of 84.6%
• BNT323/DB-1303 is a topoisomerase-1 inhibitor-based ADC targeting HER2 & was built from DualityBio’s Duality Immune Toxin Antibody Conjugates platform

Ref: BioNTech | Image: BioNTech

Related News:- Moderna's Patent Revoked by the European Patent Office (EPO) due to BioNTech Vaccine Dispute

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com